Global Cardiac Mapping Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product (EP Ablation Catheters, EP Laboratory Devices, EP Diagnostic Catheters, Access Devices), By Indication (Atrial Fibrillation, Atrial Flutter, Atrioventricular Nodal Reentry Tachycardia, Wolff-Parkinson-White Syndrome), End-User (Hospitals And Clinics, Diagnostic Centres) And By Geography - Forecasts From 2020 To 2025

Published: Apr 2021 | Report Code:  KSI061613782 | Pages:  120

The global cardiac mapping market is projected to grow at a CAGR of 9.46% to reach US$1,527.102 million by 2025 from US$887.841 million in 2019.

Atrial fibrillation is a growing serious condition that affects the heart and the major causes include an unhealthy lifestyle that many individuals lead. According to the American Heart Association, there are about 2.3 million people in the United States alone, that suffer from atrial fibrillation, and this problem significantly increases the risk of getting a stroke. Moreover, according to the statistical data provided by the NHS (National Health Service), Arrhythmia is a problem that is also known as heart rhythm problems and approximately faced and experienced by more than 2 million people a year in the UK. The most common types of arrhythmia that people suffer from include atrial fibrillation, which is a condition in which the heart is beating at an irregular and faster than normal pace. One of the reasons that can result in atrial fibrillation is the consumption of high amounts of alcohol or unhealthy eating habits, such as a diet with high levels of fats and cholesterol, which tend to block the arteries. Therefore, these factors are leading to individuals going for health checkups more often and opt for accurate and effective heart health checkups or EP exams. This is leading to an increase in the adoption of cardiac mapping products and devices, thereby augmenting the market growth over the forecast period.

New and Effective techniques that are able to successfully treat atrial fibrillation are providing opportunities for the market players that they can harness and boost their market position as well as accelerate the market growth

There are many advancements and enhanced procures and techniques that are coming up in order to treat the problem of Atrial Fibrillation, which is a growing and persistent problem. Recently, in March 2020, a clinical trial that makes the use of pulse-field energy in order to heal patients and poses as a novel approach to treat this and achieve more desirable and accurate patient outcomes. The trial of this method was conducted by the Heart Rhythm Society (HRS) 2020 and was also published in Circulation Arrhythmia and Electrophysiology. The test compared the tissue selectivity of the PFA technique over the Radon Frequency ablation (RF) technique. Therefore, groundbreaking tests and findings such as these are providing the market players with an opportunity to enhance and upgrade their product line by adding products catering to this method and contribute to the market growth over the forecast period.

Product Offerings by Major Market Players in the Cardiac Mapping Market

Furthermore, the interest being shown by the market payers in order to provide the end-users such hospitals and diagnostic centers with innovative and advanced cardiac mapping products fueling the market growth further over the forecast period

Some of the examples of product offerings are as follows:

  • Recently, in May 2020, Biotronik announced that they have partnered up with Acutus Medical in order to provide a comprehensive service portfolio of electrophysiology, mapping, ablation, and some other accessory products in order to facilitate catheter-based treatment of cardiac arrhythmias. The product is being launched across the regional markets in Europe and Asia. Their product is called the “Acutus AcQMap System. This product is developed with multi-mode mapping capabilities and is a non-contact mapping stem that is able to facilitate the mapping of unstable and stable rhythms. In addition, it is able to optimize the treatment of different types of arrhythmia in under 3 minutes.
  • In October 2019, Baylis Medical, which is considered as one of the leading manufacturing companies for cardiology devices so as to aid the physicians, announced the first use of its new product line called its product, “ EPstar Fixed Electrophysiology Catheters “. The product line includes the “2-French Electrophysiology Catheter”, the “6F guiding catheter” for allowing deeper coronary sinus mapping (CS mapping). In addition, the EPstar catheters are able to make available the smallest catheters available for the diagnosis available in the North American electrophysiology market and in turn allowing the physicians to carry out more effective cardiac mapping.

The North American region is estimated to hold a significant market share over the forecast period owing to the rising geriatric population and the Asia Pacific region is estimated to increase its market share owing to the initiatives being taken in order to boot the medical and healthcare infrastructure of countries such as India.

The North American region is estimated to hold a significant share over the forecast period owing to the well-established healthcare industry and the availability of quality healthcare services, coupled with the early adoption of advanced and enhanced medical devices and detection products, which are being made available by the market players. In addition, to this, the growing geriatric population and the increased risk posed by heart problems posed to them are among other reasons for the rising demand for cardiac mapping in countries such as the US.

The Asia Pacific region is estimated to increase its share over the forecast period owing to the initiatives being taken and the investment being made in order to develop the medical infrastructure in the countries such as India in order to provide better healthcare facilities available to the population.


  • By Product
    • EP Ablation Catheters
    • EP Laboratory Devices
    • EP Diagnostic Catheters
    • Access Devices
  • By Indication
    • Atrial Fibrillation
    • Atrial Flutter
    • Atrioventricular Nodal Reentry Tachycardia
    • Wolff-Parkinson-White Syndrome
  • By End-User
    • Hospitals and Clinics
    • Diagnostic Centres
  • By Geography
    • North America
    • USA
    • Canada
    • Mexico
    • South America
    • Brazil
    • Argentina
    • Others
    • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
    • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
    • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Others

Frequently Asked Questions (FAQs)

Q1. What will be the cardiac mapping market size by 2025?
A1. The global cardiac mapping market is projected to reach a market size of US$1,527.102 million by 2025.
Q2. What is the size of global cardiac mapping market?
A2. Cardiac Mapping market was valued at US$887.841 million in 2019.
Q3. What are the growth prospects for cardiac mapping market?
A3. The cardiac mapping market is projected to grow at a CAGR of 9.46% over the forecast period.
Q4. How is the global cardiac mapping market segmented?
A4. The global cardiac mapping market has been segmented by product, indication, end-user, and geography.
Q5. Which region holds the largest market share in the cardiac mapping market?
A5. The North American region is estimated to hold a significant share in the global cardiac mapping market.

Explore custom options available with this study:

  • Request customization

  • Buy sections of the study

  • Buy country specific report

  • Request excel, Historical data

  • Subscription inquiry

  • Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


We are in compliance with the global privacy laws.